Professor Diana Sarfati is appointed as the Ministry of Health's National Director of the newly established cancer control agency in New Zealand. At Danish Cancer Research Days 2019, Professor Diana Sarfati gave a presentation on the impact of comorbidity on cancer care.


The proportion of elderly and old cancer patients will increase in the future. The elderly cancer patient has different needs, and may need cancer treatment that is personalised in relation to their general and individual characteristics.

At Danish Cancer Research Days 2019, the subject of cancer care for the ageing population was presented by geriatrician Cecilia Lund, Herlev Hospital and Danish national initiatives presented by Professor Henrik Ditzel, University of Southern Denmark, Odense. The moderator of the session was  Professor Henrik Møller, The Danish Clinical Registries (RKKP).

Watch Professor Diana Sarfatis presentation from the session:


Diana Sarfati - The impact of comorbidity on cancer care and outcomes

Gå ind på adressen øverst på siden for at se videoen.

Diana Sarfati 

Professor Diana Sarfati is a public health physician, cancer epidemiologist and health services researcher. She is the newly appointed National Director of the cancer control agency in New Zealand. She is Head of the Department of Public Health and the Director of the Cancer and Chronic Conditions (C3) Research Group at University of Otago, Wellington. She is currently a member of the New Zealand National Cancer Leadership Board (NZ), the Advisory Committee to International Agency for Research on Cancer’s (IARC) Pacific cancer hub, the Academic Advisory Committee to IARC on the International Cancer Benchmarking Project, and she has recently led a Lancet Oncology series on cancer control in small island developing states.

Professor Sarfati’s research interests include the inter-relationships between cancer and other long-term conditions. She has also led a large body of research relating to disparities in cancer outcomes in New Zealand. Her work has resulted in the identification of key patient and health system factors that influence cancer survival. It has been used extensively by health policy makers, clinicians and other researchers to develop policies and practices that aim to improve cancer outcomes and to reduce inequities in outcomes.